KR101107949B1 - 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도 - Google Patents

트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도 Download PDF

Info

Publication number
KR101107949B1
KR101107949B1 KR1020097018289A KR20097018289A KR101107949B1 KR 101107949 B1 KR101107949 B1 KR 101107949B1 KR 1020097018289 A KR1020097018289 A KR 1020097018289A KR 20097018289 A KR20097018289 A KR 20097018289A KR 101107949 B1 KR101107949 B1 KR 101107949B1
Authority
KR
South Korea
Prior art keywords
receptor
compound
nonspecific
compounds
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097018289A
Other languages
English (en)
Korean (ko)
Other versions
KR20090108115A (ko
Inventor
라제쉬 벤카테스바란 데브라즈
크레센조 개리 에이 데
지아오 후
케빈 드웨인 제롬
마크 제라드 오브코위츠
리사 올슨
폴 빈센트 럭커
로날드 케이쓰 웨버
Original Assignee
화이자 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20090108115A publication Critical patent/KR20090108115A/ko
Application granted granted Critical
Publication of KR101107949B1 publication Critical patent/KR101107949B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
KR1020097018289A 2007-02-02 2008-01-25 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도 Expired - Fee Related KR101107949B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
US60/887,981 2007-02-02
PCT/IB2008/000229 WO2008093227A1 (en) 2007-02-02 2008-01-25 Tricyclic compounds and their use as glucocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
KR20090108115A KR20090108115A (ko) 2009-10-14
KR101107949B1 true KR101107949B1 (ko) 2012-02-08

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097018289A Expired - Fee Related KR101107949B1 (ko) 2007-02-02 2008-01-25 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
KR1020097018294A Expired - Fee Related KR101114682B1 (ko) 2007-02-02 2008-01-28 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097018294A Expired - Fee Related KR101114682B1 (ko) 2007-02-02 2008-01-28 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이의 용도

Country Status (42)

Country Link
US (7) US7547714B2 (https=)
EP (1) EP2114970B1 (https=)
JP (1) JP4599462B2 (https=)
KR (2) KR101107949B1 (https=)
CN (2) CN101616925B (https=)
AP (1) AP2455A (https=)
AR (2) AR065135A1 (https=)
AT (1) ATE518872T1 (https=)
AU (1) AU2008211613B2 (https=)
BR (1) BRPI0808634A2 (https=)
CA (1) CA2676670C (https=)
CL (2) CL2008000330A1 (https=)
CO (2) CO6190603A2 (https=)
CR (2) CR10948A (https=)
CU (2) CU23824A3 (https=)
CY (2) CY1110962T1 (https=)
DK (1) DK2114970T3 (https=)
DO (1) DOP2009000190A (https=)
EA (1) EA016494B1 (https=)
EC (2) ECSP099553A (https=)
ES (2) ES2368286T3 (https=)
GE (2) GEP20125404B (https=)
GT (2) GT200900210A (https=)
HN (2) HN2008000178A (https=)
HR (1) HRP20110702T1 (https=)
IL (1) IL199972A (https=)
MA (2) MA31158B1 (https=)
MX (1) MX2009008284A (https=)
MY (3) MY153057A (https=)
NI (2) NI200900149A (https=)
NZ (1) NZ578638A (https=)
PE (2) PE20081736A1 (https=)
PL (1) PL2114970T3 (https=)
PT (2) PT2114970E (https=)
RS (2) RS51970B (https=)
SI (1) SI2114970T1 (https=)
SV (2) SV2009003346A (https=)
TN (1) TN2009000324A1 (https=)
TW (2) TWI347842B (https=)
UA (2) UA94639C2 (https=)
WO (1) WO2008093227A1 (https=)
ZA (2) ZA200906064B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
HRP20110702T1 (hr) * 2007-02-02 2011-10-31 Pfizer Products Inc. Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora
ES2527137T3 (es) 2008-07-28 2015-01-21 Pfizer Inc. Compuestos de fenantrenona, composiciones y procedimientos
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
KR20130106378A (ko) * 2010-08-27 2013-09-27 코어셉트 쎄라퓨틱스, 잉크. 피리딜-아민 융합된 아자데칼린 조절제
WO2012125797A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Nuclear hormone receptor modulators
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
MX389718B (es) 2014-05-16 2025-03-20 Olaplex Inc Formulaciones y metodos de tratamiento con queratina.
EP3848028B9 (en) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
WO2016149756A1 (en) 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
MX385698B (es) 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
JP7614646B2 (ja) 2018-11-07 2025-01-16 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処置のための化合物及び組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756814A (en) * 1986-06-19 1988-07-12 Aluminum Pechiney Method for the individual marking of precooked anodes for the electrolytic production of aluminum
US20020060629A1 (en) * 2000-11-20 2002-05-23 Pfeiffer Michael W. RF ID tag attachment to a disc drive
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
MXPA01011018A (es) * 1999-04-30 2002-05-06 Pfizer Prod Inc Moduladores del receptor glucocorticoide.
WO2001005229A1 (en) 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
ES2262612T3 (es) * 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
CA2450748A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
IL160649A0 (en) 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome
WO2003029217A2 (en) 2001-09-27 2003-04-10 Universite De Liege Pyridinic sulfonamide derivatives, method of production and use thereof
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CN1665515A (zh) 2002-07-02 2005-09-07 科塞普特治疗公司 治疗与干扰素α治疗相关的精神病的方法
JP4503436B2 (ja) 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
JP2006508951A (ja) 2002-11-05 2006-03-16 コーセプト セラピューティクス， インコーポレイテッド 片頭痛を処置するための方法
EP1599208A4 (en) 2003-02-04 2007-09-12 Corcept Therapeutics Inc ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF POSTPARTAL PSYCHOSIS
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
WO2005047524A2 (en) * 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2545020A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja) 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP2114888B1 (en) * 2007-02-02 2010-11-10 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
HRP20110702T1 (hr) * 2007-02-02 2011-10-31 Pfizer Products Inc. Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756814A (en) * 1986-06-19 1988-07-12 Aluminum Pechiney Method for the individual marking of precooked anodes for the electrolytic production of aluminum
US20020060629A1 (en) * 2000-11-20 2002-05-23 Pfeiffer Michael W. RF ID tag attachment to a disc drive
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode

Also Published As

Publication number Publication date
NI200900149A (es) 2010-02-15
US7547714B2 (en) 2009-06-16
IL199972A (en) 2013-09-30
IL199972A0 (en) 2010-04-15
PT2114970E (pt) 2011-09-22
CU20090132A7 (es) 2011-10-14
RS51970B (sr) 2012-02-29
HN2008000178A (es) 2011-02-25
NI200900148A (es) 2010-02-15
ECSP099552A (es) 2009-08-28
EP2114970A1 (en) 2009-11-11
PT2114888E (pt) 2011-01-04
CU23848B1 (es) 2012-10-15
TWI373466B (en) 2012-10-01
UA95332C2 (uk) 2011-07-25
US20140316139A1 (en) 2014-10-23
CL2008000330A1 (es) 2008-08-08
MY153057A (en) 2014-12-31
KR101114682B1 (ko) 2012-03-14
US20090281148A1 (en) 2009-11-12
WO2008093227A1 (en) 2008-08-07
CA2676670A1 (en) 2008-08-07
DK2114970T3 (da) 2011-09-19
GT200900209A (es) 2010-07-22
SI2114970T1 (sl) 2011-11-30
CL2008000329A1 (es) 2008-08-08
CR10948A (es) 2009-08-07
ES2353822T3 (es) 2011-03-07
CO6220937A2 (es) 2010-11-19
HRP20110702T1 (hr) 2011-10-31
JP4599462B2 (ja) 2010-12-15
HK1135108A1 (en) 2010-05-28
RS51646B (sr) 2011-10-31
AR065135A1 (es) 2009-05-20
US8901310B2 (en) 2014-12-02
CN101616925B (zh) 2012-05-23
MY146087A (en) 2012-06-29
CU20090133A7 (es) 2011-10-31
SV2009003346A (es) 2010-04-13
US20120088802A9 (en) 2012-04-12
ECSP099553A (es) 2009-08-28
CN101616896B (zh) 2012-07-04
BRPI0808634A2 (pt) 2014-08-05
MY148780A (en) 2013-05-31
ATE518872T1 (de) 2011-08-15
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
CR10949A (es) 2009-08-07
TN2009000324A1 (fr) 2010-12-31
AP2455A (en) 2012-08-31
US20080312294A1 (en) 2008-12-18
US7598231B2 (en) 2009-10-06
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
US20100286214A1 (en) 2010-11-11
EP2114970B1 (en) 2011-08-03
MA31158B1 (fr) 2010-02-01
PE20090113A1 (es) 2009-02-13
US8445520B2 (en) 2013-05-21
CO6190603A2 (es) 2010-08-19
UA94639C2 (ru) 2011-05-25
MA31117B1 (fr) 2010-01-04
ZA200906060B (en) 2010-05-26
CN101616925A (zh) 2009-12-30
ES2368286T3 (es) 2011-11-16
DOP2009000190A (es) 2009-08-31
CN101616896A (zh) 2009-12-30
GT200900210A (es) 2010-04-05
US7786097B2 (en) 2010-08-31
TW200838514A (en) 2008-10-01
HN2008000179A (es) 2010-06-09
TWI347842B (en) 2011-09-01
GEP20125404B (en) 2012-02-27
CA2676670C (en) 2012-03-13
JP2010517990A (ja) 2010-05-27
TW200846325A (en) 2008-12-01
KR20090107080A (ko) 2009-10-12
AR065134A1 (es) 2009-05-20
SV2009003349A (es) 2010-04-13
CY1111758T1 (el) 2015-10-07
EA200970666A1 (ru) 2010-02-26
US20080188443A1 (en) 2008-08-07
NZ578638A (en) 2010-12-24
PL2114970T3 (pl) 2011-11-30
US20140142316A1 (en) 2014-05-22
US20120095062A1 (en) 2012-04-19
EA016494B1 (ru) 2012-05-30
GEP20125426B (en) 2012-03-26
AU2008211613A1 (en) 2008-08-07
ZA200906064B (en) 2010-05-26
AP2009004942A0 (en) 2009-08-31
KR20090108115A (ko) 2009-10-14
MX2009008284A (es) 2009-08-12
CU23824A3 (es) 2011-10-31

Similar Documents

Publication Publication Date Title
KR101107949B1 (ko) 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
EP2114888B1 (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
HK1135108B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
HK1135094B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20141230

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190113